![]() ![]() For developing or low-income countries, the cost of the treatment is simply unaffordable for a majority of patients. ![]() Of note, cost-effectiveness of chemotherapy-ICI is under intense debate for health systems in developed countries (i.e., USA, China) ( 8). The robust positive results of Keynote-407 have led to both FDA ( 3) and EMA ( 4) approvals of pembrolizumab combined with carboplatin and paclitaxel/nab-paclitaxel for frontline therapy in advanced SqNSCLC, with the support of scientific societies in USA ( 5, 6) and Europe ( 7). ICI-chemotherapy combination for SqNSCLC is a game-changer that has broaden and revitalized the clinical spectrum of possibilities for thoracic oncologists. A total of 559 patients were randomized and stratified, among other factors, by PD-L1 tumor proportion score (TPS) negativity (50% expression of PD-L1 and as a second-line therapy regardless PD-L1 status, paving the way for further explorations of cancer immunotherapy in SqNSCLC. Crossover to pembrolizumab monotherapy in case of treatment failure in the placebo-group was allowed. After induction treatment of 4 cycles, a pembrolizumab/placebo maintenance was indicated up to 35 cycles. They reported the results of the Keynote-407 ( 1) study, a multicentric, double-blind, placebo controlled, randomized trial which investigated the role of the addition of pembrolizumab to platinum doublet chemotherapy (carboplatin and paclitaxel or nanoparticle albumin-bound paclitaxel) compared to placebo in first-line setting for patients with advanced squamous non-small-cell lung cancer (SqNSCLC). published at the New England Journal of Medicine “Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer”. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The article did not undergo external peer review.Ĭomment on: Paz-Ares L, Luft A, Vicente D, et al. Email: and Peer Review: This article was commissioned by the editorial office, Translational Lung Cancer Research. Sabino Arana 5-19, Barcelona 08028, Spain. Interviews with Outstanding Guest EditorsĬorrespondence to: Santiago Viteri.Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |